ドキソルビシン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H302：飲み込むと有害

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

  H350：発がんのおそれ

  H362：授乳中の子に害を及ぼすおそれ

• 注意書き

  P260：粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。

  P263：妊娠中/授乳期中は接触を避けること。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

MSDS Information

• (1S,3S)-3,5,12-Trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

ドキソルビシン 化学特性,用途語,生産方法

• 解説

  塩ドキソルビシン，赤橙色の針状晶．分解点204～205 ℃．[α]²⁰_D＋248°(メタノール)．UV(メタノール)λmax 233，252，288，479，496，529 nm．DNAに層間挿入して核酸合成を阻害する．トポイソメラーゼⅡを阻害してDNA鎖切断をする．急性リンパ性白血病，リンパ腫，乳がん，小細胞肺がん，卵巣がんなどの治療に広く使われる．

  森北出版「化学辞典（第2版）
  

• 用途

  ドキソルビシン（doxorubicin）は、抗悪性腫瘍剤（抗がん剤）の一種。

• 製造

  ドキソルビシン，アドリアマイシンともいう．Streptomyces peucetius var caesiusが産生するアンスラサイクリン系抗生物質．

• 効能

  抗悪性腫瘍薬, トポイソメラーゼII阻害薬

• 毒性

  LD50 698 mg/kg(マウス，経口)．

• 化学的特性

  Adriamycin is an orange to red cake-like or needle-like crystalline solid.

• 来歴

  Adriamycin was first discovered in 1967 by Arcamone, Cassinelli, Di Marco, and Gaetani at the FI Research Laboratory.  It was found in cultures of a mutant Streptomyces peucetius (Streptomyces peucetius caesius) (Arcamone, 1969).  The compound's chemical structure is very similar to daunomycin, the only difference being that a hydrogen atom on the acetyl group is replaced by a hydroxyl group.  The new compound is named after the view of the Adriatic Sea from Castel del Monte, where the strain that produced it was isolated. Subsequently, researchers conducted extensive preclinical, pharmacological, toxicological, and formulation studies. However, it wasn't until 1969, when Monfardini published authoritative results in a journal confirming the drug's broad activity spectrum, that it gained widespread attention from the scientific community.

• 使用

  Doxorubicin (adriamycin) is the most extensively studied of a family of highly fluorescent anthracycline antibiotics produced by several Streptomyces species, first reported in 1967 and later approved for human therapeutic use as an antitumour agent for the treatment of a wide range of cancers. Doxorubicin also exhibits anti-HIV and antibacterial activity. The mode of action of doxorubicin is thought to be due to intercalation of DNA and inhibition of nucleic acid synthesis.

• 適応症

  Doxorubicin binds tightly to DNA by its ability to intercalate between base pairs and therefore is preferentially concentrated in nuclear structures. Intercalation results in steric hindrance, hence production of single-strand breaks in DNA and inhibition of DNA synthesis and DNA-dependent RNA synthesis. The enzyme topoisomerase II is thought to be involved in the generation of DNA strand breaks by the anthracyclines. Cells in S-phase are most sensitive to doxorubicin, although cytotoxicity also occurs in other phases of the cell cycle.

• 作用機序

  Doxorubicin is not absorbed orally, and because of its ability to cause tissue necrosis must not be injected intramuscularly or subcutaneously. Distribution studies indicate rapid uptake in all tissues except the CNS. Extensive tissue binding, primarily intranuclear, accounts for the prolonged elimination half-life.The drug is extensively metabolized in the liver to hydroxylated and conjugated metabolites and to aglycones that are primarily excreted in the bile.

• 臨床応用

  Doxorubicin is one of the most effective agents used in the treatment of carcinomas of the breast, ovary, endometrium, bladder, and thyroid and in oat cell cancer of the lung. It is included in several combination regimens for diffuse lymphomas and Hodgkin’s disease. Doxorubicin can be used as an alternative to daunorubicin in acute leukemias and is useful in Ewing’s sarcoma, osteogenic sarcoma, soft-tissue sarcomas, and neuroblastoma. Some activity has been reported in non–oat cell lung cancer, multiple myeloma, and adenocarcinomas of the stomach, prostate, and testis.

• 副作用

  The most important toxicities caused by doxorubicin involve the heart and bone marrow.Acutely, doxorubicin may cause transient cardiac arrhythmias and depression of myocardial function. Doxorubicin may cause radiation recall reactions, with flare-ups of dermatitis, stomatitis, or esophagitis that had been produced previously by radiation therapy. Less severe toxicities include phlebitis and sclerosis of veins used for injection, hyperpigmentation of nail beds and skin creases, and conjunctivitis. Because of its intense red color, doxorubicin will impart a reddish color to the urine for 1 or 2 days after administration.

• 安全性プロファイル

  Confirmed carcinogen with experimental carcinogenic, neoplastigenic, and tumorigenic data. Poison by intraperitoneal, subcutaneous, parenteral, and intravenous routes. Human systemic effects by intravenous route: cardiac myopathy including infarction, nausea or vomiting, and effects on the hair. An experimental teratogen. Other experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of NO, and HCl

• 職業ばく露

  An antibiotic product from streptomyces, used as anticancer drug

• 発がん性

  Adriamycin is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.

• 輸送方法

  UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required.

• 不和合性

  Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides

• 廃棄物の処理

  It is inappropriate and possibly dangerous to the environment to dispose of expired or waste pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

ドキソルビシン 上流と下流の製品情報

ドキソルビシン 生産企業

Global(286)Suppliers

ドキソルビシン スペクトルデータ(¹HNMR)

23214-92-8, ドキソルビシン キーワード